2025 PACUPrep BCCCP Preparatory Course Sepsis and Septic Shock Escalating Pharmacotherapy in Sepsis and Septic Shock
Escalating Pharmacotherapy in Sepsis and Septic Shock

Escalating Pharmacotherapy in Sepsis and Septic Shock

Objective Icon A clipboard with a target symbol, representing a clinical objective.

Objective

Design an evidence-based, tiered pharmacotherapy regimen for patients with sepsis and septic shock, integrating antimicrobial and vasoactive strategies with PK/PD principles, adjunctive therapies, and stewardship considerations.

1. Empiric Antimicrobial Therapy

Rapid initiation of broad-spectrum antibiotics within 1 hour of septic shock recognition is the cornerstone of therapy. The choice of agent must reflect the suspected source of infection, local resistance patterns, patient-specific risk factors, and pharmacokinetic/pharmacodynamic (PK/PD) targets for optimal bacterial killing.

A. Timing and Initiation

  • Septic Shock: Administer empiric broad-spectrum antibiotics immediately, with a goal of within 1 hour of identification.
  • Sepsis without Shock: Aim for antibiotic delivery within 3 hours of diagnosis, allowing for a more deliberate diagnostic workup.
  • Process Improvement: Utilize standardized order sets, sepsis carts, and regular time-to-antibiotic audits to minimize delays and improve compliance.

B. Agent Selection

  • Source Control: Base the empiric regimen on the suspected source (e.g., intra-abdominal, pulmonary, urinary, catheter-related).
  • Local Antibiogram: Consult local resistance data to ensure reliable coverage for common pathogens, especially gram-negative organisms like Pseudomonas aeruginosa.
  • MDR Risk Assessment: Assess for risk factors for multidrug-resistant (MDR) organisms, including prior colonization, recent broad-spectrum antibiotic use, and significant healthcare exposure.
  • Anti-MRSA Coverage: Add vancomycin or linezolid if risk factors for methicillin-resistant Staphylococcus aureus (MRSA) are present or if the patient has severe illness.

C. PK/PD Optimization and Dosing

  • β-Lactams: Administer a loading dose over 30 minutes, followed by a prolonged (3–4 hours) or continuous infusion to maximize the time the free drug concentration remains above the minimum inhibitory concentration (fT>MIC).
  • Aminoglycosides: Use once-daily, high-dose “concentration-dependent” dosing. Monitor peaks (target 8–10 times the MIC) and troughs to ensure efficacy while avoiding nephrotoxicity and ototoxicity.
  • Renal Replacement Therapy (RRT): Continuous RRT significantly increases the clearance of hydrophilic drugs (e.g., β-lactams, vancomycin). Consider increasing the dose by approximately 25% or shortening the dosing interval to avoid subtherapeutic concentrations.
  • Hepatic Impairment: Expect reduced clearance of lipophilic agents (e.g., linezolid, metronidazole) and potentially altered protein binding. Dose adjustments may be necessary.

D. De-escalation and Stewardship

Antimicrobial stewardship is not a barrier to care but an essential component of it. The goal is to use the right drug, for the right bug, for the right duration.

Antimicrobial De-escalation Flowchart A flowchart showing the daily process for antimicrobial stewardship in sepsis. It starts with daily reassessment, moves to checking culture results, and branches to either narrowing the antibiotic spectrum or continuing broad coverage if no pathogen is identified, with a final step to consider discontinuation. Daily Reassessment (Clinical Status) Review Cultures & Susceptibilities Pathogen ID’d: Narrow Spectrum No Pathogen ID’d: Reassess Need
Figure 1: Antimicrobial Stewardship Daily Workflow. Daily reassessment is crucial. Once culture and susceptibility data are available, therapy should be narrowed. If cultures are negative and the patient is improving, consider discontinuing antibiotics.
Pearl IconA lightbulb icon, representing a key point or clinical pearl. Key Points: Antimicrobial Therapy
Expand/Collapse Icon
  • The One-Hour Rule: In septic shock, every hour of delay in administering appropriate antibiotics is associated with a measurable increase in mortality.
  • Optimize Infusions: Prolonged or continuous infusion of β-lactams improves PK/PD target attainment in critically ill patients, particularly against less susceptible organisms.
  • De-escalate Safely: Narrowing antibiotic spectrum based on culture results reduces toxicity, selection pressure for resistance, and cost, without compromising patient outcomes.

2. Vasoactive and Hemodynamic Agents

The primary hemodynamic goal in septic shock is to restore tissue perfusion by achieving a mean arterial pressure (MAP) of at least 65 mm Hg. Norepinephrine is the first-line agent, with adjunctive therapies added based on the patient’s response and the dose of catecholamines required.

Comparison of Vasoactive Agents in Septic Shock
Agent Mechanism & Role Typical Dose Key Considerations
Norepinephrine Potent α₁-agonist (vasoconstriction) with modest β₁-agonist (inotropy). First-line vasopressor. Start 0.05–0.1 µg/kg/min; titrate to MAP ≥65 mm Hg. Can cause peripheral/splanchnic ischemia at high doses. Monitor for reflex bradycardia.
Vasopressin V1 receptor agonist; catecholamine-sparing. Adjunct for refractory shock. Fixed dose: 0.03 units/min. Not titrated. Add when norepinephrine dose is escalating (>0.2 µg/kg/min). Monitor for hyponatremia and digital ischemia.
Epinephrine Potent α and β agonist. Reserved for refractory shock or cardiogenic component. Start 0.05–0.1 µg/kg/min; titrate to effect. High risk of tachyarrhythmias and can increase lactate levels (not necessarily from hypoperfusion).
Dopamine Dose-dependent effects (dopaminergic, β, α). Generally avoided. 2–20 µg/kg/min. Higher rate of arrhythmias compared to norepinephrine. May be considered in absolute bradycardia with hypotension.

C. Corticosteroid Adjuncts

Corticosteroids are recommended for patients with persistent vasopressor-dependent shock despite adequate fluid resuscitation and escalating vasopressor requirements.

  • Indication: Septic shock requiring ongoing vasopressor support (e.g., norepinephrine ≥0.25 µg/kg/min) to maintain MAP ≥65 mm Hg.
  • Recommended Regimen: Hydrocortisone 200 mg/day, administered as a continuous infusion or as 50 mg IV every 6 hours. The addition of fludrocortisone 50 µg enterally once daily has been shown to improve outcomes.
  • Monitoring: Closely monitor for hyperglycemia, hypernatremia, hypokalemia, and secondary infections.
Controversy IconA chat bubble with a question mark, indicating a point of controversy or debate. Controversies in Corticosteroid Use
Expand/Collapse Icon

The use of corticosteroids in septic shock has been debated for decades. While recent large trials (ADRENAL, APROCCHSS) have clarified their role, some controversies remain:

  • Patient Selection: The exact vasopressor dose threshold to initiate steroids is not universally agreed upon.
  • Mineralocorticoid Effect: The necessity of adding fludrocortisone to hydrocortisone is debated, though the APROCCHSS trial showed a mortality benefit with the combination.
  • Weaning Strategy: The optimal method for discontinuing steroids (abrupt stop vs. slow taper) after shock resolution is unclear.

3. Monitoring, Pharmacoeconomics, and Quality Considerations

Effective management of septic shock extends beyond drug selection to include ongoing assessment of drug exposure, efficacy markers, potential toxicities, and overall value. This ensures safe, evidence-based, and cost-effective care.

A. Therapeutic Drug Monitoring (TDM) and Efficacy Markers

  • Vancomycin TDM: Target an Area Under the Curve (AUC) to MIC ratio of 400–600 mg·h/L to balance efficacy and minimize the risk of acute kidney injury.
  • Lactate Clearance: A decrease in serum lactate of at least 10% within the first 2 hours of resuscitation is a key marker of improving perfusion and is associated with improved survival.
  • Organ Function: Track daily Sequential Organ Failure Assessment (SOFA) scores to monitor the trajectory of organ dysfunction. Improvement in the SOFA score is a strong indicator of successful resuscitation.

B. Safety Surveillance

  • Renal and Hepatic Function: Monitor daily creatinine, BUN, and liver function tests to detect drug-induced organ injury early.
  • Hematologic Effects: Check complete blood counts regularly, especially for thrombocytopenia in patients receiving linezolid.
  • Metabolic Monitoring: During corticosteroid therapy, monitor blood glucose and electrolytes (sodium, potassium) at least twice daily.

C. Cost-Effectiveness and Resource Allocation

  • Dosing Strategies: While prolonged β-lactam infusions may require more pharmacy and nursing resources initially, they can lead to overall cost savings by potentially shortening ICU length of stay.
  • Agent Selection: The higher acquisition cost of vasopressin may be offset by a reduction in total norepinephrine dose and a potential decrease in the incidence of new-onset atrial fibrillation or need for RRT.
  • Stewardship Integration: Interdisciplinary stewardship rounds, sepsis response teams, and the use of pre-stocked “sepsis carts” can streamline care, improve guideline adherence, and ensure resources are used efficiently.
Pearl IconA lightbulb icon, representing a key point or clinical pearl. Key Points: Monitoring & Stewardship
Expand/Collapse Icon
  • Integrate Workflows: Schedule therapeutic drug monitoring draws to align with routine ICU lab draws to prevent missed or delayed levels.
  • Value-Based Decisions: Use institutional cost and outcome data to inform formulary decisions and dosing strategies, balancing acquisition price with overall clinical and economic impact.
  • Continuous Improvement: Implement ongoing education and performance feedback loops for clinical teams to reinforce best practices, improve guideline adherence, and ultimately enhance patient outcomes.

References

  1. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063–e1143.
  2. Nofal MA, Shitawi J, Altarawneh HB, et al. Recent trends in septic shock management: a comprehensive review of the literature. Ann Med Surg (Lond). 2024;86(9):4532–4540.
  3. Kondo Y, Ota K, Imura H, et al. Prolonged vs intermittent β-lactam infusion in patients with sepsis: a systematic review and meta-analysis of randomised controlled trials. J Intensive Care. 2020;8:77.
  4. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009;66(1):82–98.
  5. Kellum JA, Angus DC, Johnson JP, et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med. 2002;28(1):29–37.
  6. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789.
  7. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA. 2016;316(5):509–518.
  8. Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Septic Shock. N Engl J Med. 2018;378(9):809–818.
Previous Topic
Back to Lesson
Next Topic